HMG20B Antikörper (AA 1-100)

Produktnummer ABIN1714340

Produktdetails anti-HMG20B Antikörper

Target: HMG20B (High Mobility Group 20B (HMG20B))

Bindungsspezifität: AA 1-100

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HMG20B Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))

Kreuzreaktivität: Maus

Homologie: Human,Rat,Cow

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human BRAF35

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu HMG20B

Target: HMG20B (High Mobility Group 20B (HMG20B))

Andere Bezeichnung: BRAF35 (HMG20B Produkte)

Synonyme: BRAF25 antikoerper, BRAF35 antikoerper, HMGX2 antikoerper, HMGXB2 antikoerper, PP7706 antikoerper, SMARCE1r antikoerper, SOXL antikoerper, pp8857 antikoerper, AW610687 antikoerper, Hmgx2 antikoerper, Hmgxb2 antikoerper, Smarce1r antikoerper, high mobility group 20 B antikoerper, high mobility group 20B antikoerper, Hmg20b antikoerper, HMG20B antikoerper

Hintergrund:

Synonyms: BRAF25, BRAF35, BRCA 2 Associated Factor 35 kDa, BRCA2 associated factor 35, BRCA2-associated factor 35, High Mobility Group Protein 20B, HM20B_HUMAN, HMG 20B, HMG box containing protein 20B, HMG box-containing protein 20B, HMG domain-containing protein 2, HMG domain-containing protein HMGX2, hmg20b, HMGX2, PP7706, pp8857, SMARCE1 related protein, SMARCE1-related protein, SMARCE1r, sox like, Sox like transcriptional factor, Sox-like transcriptional factor, SOXL, Structural DNA binding protein BRAF35, Structural DNA-binding protein BRAF35, SWI/SNF related, SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily E member 1 related, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related.

Background: The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45 % of families with high incidence of breast cancer and at least 80 % of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.

Gen-ID: 10362